Carcinoma, Neuroendocrine - 23 Studies Found
| Active, not recruiting |
: An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours : : 2024-11-23 |
| Completed |
: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers : : 2024-11-23 |
| Active, not recruiting |
: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor : : 2024-11-23 |